Eli Lilly (LLY) Equity Ratio (2009 - 2026)

Eli Lilly has reported Equity Ratio for 18 years, with the latest figure at 0.27 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 1196.34% year-over-year to 0.27; the trailing twelve-month figure through Mar 2026 stood at 0.27 (up 1196.34% YoY), and the FY2025 full-year result was 0.24, up 7448.86% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.27, up from 0.24 in the prior quarter.
• The five-year high for Equity Ratio was 0.27 in Q1 2026, with the low at 0.09 in Q2 2022.
• Historically, Equity Ratio has averaged 0.01 across 5 years, with a median of 0.02 in 2025.
• Annual changes were most pronounced in 2024 — Equity Ratio tumbled 3106.51% — and 2025, when it jumped 7448.86%.
• Eli Lilly's Equity Ratio stood at 0.0 in 2022, then slumped by 2660.06% to 0.05 in 2023, then soared by 106.64% to 0.0 in 2024, then surged by 7448.86% to 0.24 in 2025, then rose by 13.44% to 0.27 in 2026.
• The last three Equity Ratio figures came in at 0.27 (Q1 2026), 0.24 (Q4 2025), and 0.21 (Q3 2025), per Business Quant data.